Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives
- 3 August 2021
- journal article
- research article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 99, 108036
- https://doi.org/10.1016/j.intimp.2021.108036
Abstract
No abstract availableKeywords
This publication has 102 references indexed in Scilit:
- Updated Approaches against SARS-CoV-2Antimicrobial Agents and Chemotherapy, 2020
- Structural basis of receptor recognition by SARS-CoV-2Nature, 2020
- Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortalityInternational Journal of Antimicrobial Agents, 2020
- New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jawsOral Oncology, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- A novel coronavirus outbreak of global health concernThe Lancet, 2020
- Coronavirus disease 2019: A new severe acute respiratory syndrome from Wuhan in ChinaActa Virologica, 2020
- Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like DiseaseClinical Microbiology Reviews, 2015
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaThe New England Journal of Medicine, 2012